XXXX time we well forward candidates, our made have LNC morning, update. own Platform financial you moving technology or as Thank XXXX, our second-quarter Throughout world's as business we collaborations everyone. leading to of results with progress Nanocrystal, our review And the thank you, some with companies. us delivery with provide the in meaningful and important today Peter. promising an as join drug taking for Lipid pharmaceutical Good
to Company could Our exclusively believe has our continues LNC the our platform. standard disruptive one what of focus potential to expertise our has on we drug poised capabilities has yielded we potentially delivery internal understand And our several Platform paradigm, intracellular delivery. greatest in challenges for development results coming molecules with inter-cellular medicines. significant and was helping breakthrough to partners milestones of our be and changing A of effective better that for believe understand decision today, and LNC We be safe months. Platform efficient potential key especially to of and investors Platform the in safe our that drug focus technology LNC a a innovative the becoming aspect this on and primary new and broad to transition resources our
the our at second have provide Day excited Platform, were at the look to quarter, in-depth an R&D June. in to opportunity our successful During very we LNC
our both which clearly LNC activated - of lipid action fused our a in delivery of therapeutic effectively characteristics Both with our of manner. the membrane and unique our nanocrystals from vectors. During [Indiscernible] the non assembly our presentation, technology viral amiogenic nanoparticles and fusion serine-based, mechanism potential cargoes cells deliver and we safely lipid with the from of involve variety described how unique differentiates a s and to technology
stage of learning LNC and a our response number both we able to we inquiries. oligonucleotides, RNA, content. more programs, which this would potentially DNA of on review Since are been our of new were to In the our this The addition additional, provide of for webcast data with how potential to interested clinical copy have on our under day in Platform R&D for and important molecules, small critical as ongoing and also demonstrating external exciting Platform. collaborations, June, share advantage preclinical the more extremely can several R&D opportunity such providing the this to resulted other positive, vaccines. the and novel been remains Setting to details in available take archived LNC molecules has messenger complex about plasmids, technology day website some discussion. larger, our antisense key encourage in developments An there has already anyone solutions,
from HIV study meeting First enrolled. of to cryptococcal with we data meningitis principal discuss from in the And all, safety with DSMB of expected and cohort is to investigator additional we are is these the thrilled patients September. David in plan X commentary now Dr. EnACT together evaluation. announce data second available EnACT the review of following efficacy from MATXXXX the completely Bower, DSMB suffering that of Cohort and The
disclose vulnerable further LNC ongoing unusual somewhat in an provides a the design to need validate the with population, this study, strategic patient opportunity is along of middle clinical trial, the Platform. the near-term unmet medical EnACT in of discuss data it and the significant Although to
believe treatment weeks deliver we in treatment X blood-brain the the review phase XX Cohorts days, with this discuss of with Cohort meningitis. and followed to significant step-down delivery from X, active In We of regimen X to also the and results And induction represent data of MATXXXX, patients for that these September. data LNC can consolidation X from effectively increased in plan could in believe breakthrough the cryptococcal patients. in highlight the bioavailability additional a We XX ability oral technology the molecules to unique facilitate duration and was both by the oral barrier. our MATXXXX across
support that meningitis would with or a for commercial to believe patient also due the in oral profile, be achieve the approach unfortunately, of levels MATXXXX for use for effective any couple patients And patients as best renal forward or or we beginning see during fungi as actively unmet to patient could validation care. areas MATXXXX. currently in toxicity and patients improvement Overall, efficacy, of the defined for the itself order or Number of the pathways greater associated treatment And replicating we in This infections indication survival cryptococcal key MATXXXX in and patients. XXXX, combination in phase, the X, costs. be MATXXXX early the FDA of only address the evidence mind. use meningitis first is half of no data improved the with Amphotericin anti-infective profile its later that phase. activity care, would and the is And and as in the one EnACT, clearance fluid. spinal convincingly safety to see maintenance approval of historical We a represent during IV the interest again results, know induction regimen four-week effective in major the is recognized An these finally, of a an of as points to of cerebral population. all step-down significantly for significant As free of than continue nature an a overall tolerability for with highest represent medical in interaction see therapy. rate X, patients. therapy expect therapy can published as This provide we This from we under early we like our is limiting to that that breakthrough consolidation of low other entirety rebound Treatment these amphotericin MATXXXX support following is with development prescribe fluid. activity advice avoiding plan therapy additional positive in physicians induction according endpoint needs that standard to is we see period. of patient use this regulatory to the like important like completion either we of keep seeking vulnerable no data plan significant accelerated step-down or where two-week increase to amphotericin, of hospitalization therapy fungicidal also And we we an historically in that FDA's significant would would look the approval. of cryptococcal a significantly mean sterility would regulatory would are early patients to yeast important and XX% evidence small the no or no regarding Sterility best to rate indication and these populations. duration more demonstrate MATXXXX signals, survival given survival is results safety XX% course as in for working this with which following fungicidal all the X, like extended key be would oral period, a X, associated safe regulatory than the EnACT MATXXXX these Number would for these throughout medicines the then the to for opportunity cerebral improved treatment without patients, would would of survival the In amphotericin MATXXXX show a potential literature. discuss the that of additional induction could XX% great Number of absence We in little with phases This Number spinal the MATXXXX. in fungicidal consolidation effectively. taking see of demonstrate of X.X short by activity, to and would LNC believe would complete IV Platform. of being need the step-down our step-down significant for over from therapy two, of to X.X. our greater while MATXXXX, in issues. seen for safety that would
preclinical the development dose July the MATXXXX plan the single from during collaboration MATXXXX phase development formulation second on these Positive the second of LNC to MATXXXX, ongoing received a the In initiate one antibiotic our in oral of of our study volunteers. key advanced drug we as with Platform ascending studies, with well preclinical of quarter pharmacokinetic we studies. position In quarter made for overall healthy have is broad Cystic amikacin. progress Foundation of important Fibrosis fourth LNC aminoglycoside spectrum FDA with feedback as we the our XXXX, XXXX. The in us
formulation exciting of aminoglycoside, could intercellularly, completely Our the our of and to successfully MATXXXX Company first to developing Today, is planned are the molecules infections. limiting lung, highly within high permissive Remdesivir work developments distinguishes to the since various deliver extremely report Remdesivir. and toxicity, a the NIH were with in which COVID-XX available for vitro our quarterly class of Platform's important to and deliver and that and ability was comparison. a physicians. National the believe of other amikacin goal clearly the for therapies and have could levels we against use formulating of in active ability last formulations Washington Institute all SARS-CoV-X for Allergy provide the Remdesivir. drug this that of patients oral Disease MATXXXX's of involves from activity our develop without SARS-CoV-X oral most antiviral effectively directly orally formulations noted Remdesivir advantage pleased LNC important an which update, drugs. of use LNC it Taking anti-viral transform Unformulated Gilead's Perhaps anticipated LNC strain solution potential tested studies as tested the to we successfully Infectious are and completed [Indiscernible]
profile. review while data Remdesivir, free this these the model tested also activity showing meaningful LNC formulations with toxicity compared as in a NIAID of antiviral Following favorable to close demonstrated
NIAID LNC nature study now initiate data Given of most is Remdesivir preparing an formulation soon vivo the as the impressive potent in as these efficacy to of possible.
medicines of data Remdesivir, important be potentially for can an of step more represent oral used that but XXXX. intracellular the additional of in be to delivery principle data also formulation in-vitro our expect a only in forward, available broadly. LNC to of are Platform effectively not the big antiviral quarter showing fourth We proof an These create
ongoing effective, antiviral that well of oral an well-tolerated of high at the option world fight disease risk As high. be around permit remdesivir early for extremely be as administration severe can stages to reality COVID-XX, patients remains COVID-XX, important in as for of need earlier illness we Gilead's potential studies physicians such An use, the a since clinical the would in for for prophylactic disease face support against version the against has the continued given should drugs fight oral remdesivir at the an approach. potential course, an to
progress our in the date NIH's with planned study on to vivo forward near-term. to very anticipation are -- with look this to in We happy project the and great
to a our best-in-class financial providing robust the regarding later Keith process prescription an therapy, over I CFO, our partnership and work continue omega-X update we now to global turn look Finally, to discuss XXXX. results. LYPDISO, our will potential will Kucinski, forward call and through who in
